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Abstract: The COVID-19 pandemic has caused a surge of demand for medical supplies and spare
parts, which has put pressure on the manufacturing sector. As a result, 3D printing communities and
companies are currently operating to ease the breakdown in the medical supply chain. If no parts
are available, 3D printing can potentially be used to produce time-critical parts on demand such as
nasal swabs, face shields, respirators, and spares for ventilators. A structured search using online
sources and feedback from key experts in the 3D printing area was applied to highlight critical issues
and to suggest potential solutions. The prescribed outcomes were estimated in terms of cost and
productivity at a small and large scale. This study analyzes the number and costs of parts that can be
manufactured with a single machine within 24 h. It extrapolates this potential with the number of
identical 3D printers in the world to estimate the global potential that can help practitioners, frontline
workers, and those most vulnerable during the pandemic. It also proposes alternative 3D printing
processes and materials that can be applicable. This new unregulated supply chain has also opened
new questions concerning medical certification and Intellectual property rights (IPR). There is also a
pressing need to develop new standards for 3D printing of medical parts for the current pandemic,
and to ensure better national resilience.
Keywords: coronavirus; additive manufacturing; rapid manufacturing; COVID-19; SARS-CoV-2; 3D
printing; supply chain disruption; production; bridge manufacturing; PPE
1. Introduction
The COVID-19 pandemic has illustrated the vulnerability of conventional global supply chains.
Over the past decade, other major disruptions have also exposed this vulnerability [1,2]. For example,
the eruption of an Icelandic volcano in 2010 affected time-critical air shipments [3]. The Japanese
earthquake and tsunami in 2011 caused several months of disruption in the automotive industry [4].
Thailand’s 2011 floods had a huge impact on the supply chains of computer manufacturers in need of
hard disks drives [5]. After Hurricane Harvey in 2017, there was a mass disruption in the U.S. chemical
production, which caused shortages of essential industrial building materials [6]. The avian influenza
A (H5N1) affected trading and transportation systems in major cities, and caused a destructive effect
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on global food supply and business operation [7]. The coronavirus disease (COVID-19) pandemic
has once again demonstrated the fragility of conventional global supply chains. Cost minimization
and cost-cutting measures are the most significant drivers that lead to fragility and vulnerability
of global supply chains [7,8]. To date, a plethora of medical equipment businesses are relying on
overseas production in developing countries to minimize costs. This has led to shortages in the supply
of much-needed medical and non-medical products required to fight the COVID-19 pandemic. As
a result, there is an unprecedented shortage of personal protective equipment (PPE) for healthcare
workers, lack of ventilators and spare parts for patients, insufficient supply of sanitizer solutions, and
scarcity of coronavirus test kits for the general public. Countries that are affected have imposed bans
on the export of PPE and other products critical for health. These bans have subsequently caused a
greater disruption of medical supplies, and illustrate the vulnerability of global supplies and logistics
amid a large upheaval from the pandemic.
Over the past decade, 3D printing (additive manufacturing) has been increasingly implemented in
the medical industry. For example, medical and preoperative models [9], surgical implants [10–13], and
tools and templates for operations [14] have been fabricated using 3D printing. Major advantages of 3D
printing are its ability to offer mass customization, to produce freeform parts on demand, and to cater
to lot size indifference and other patient-specific designs [15–17]. In the current COVID-19 pandemic,
3D printing has been increasingly used to print spare parts for medical devices and protective gear, due
to the unavailability of supplies. According to the search volume data of Google, the term "3D printing"
was searched 2.2 times more in April 2020 than in the same period last year. Key benefits of 3D printing
over conventional manufacturing are faster production, digital storage and traceability of part files,
reduction in delivery time, and the ability to produce components regardless of the complexity of part
geometry [18,19].
To date, there are only a few publications related to COVID-19 and 3D printing. More specifically,
the following six topics have been investigated: open source ventilators [20], connectors for breathing
devices [21], sourcing PPE [22], pressure-regulated ventilator splitting spare parts [23], respirators [24],
and 3D printed ventilator parts [25]. Thus, there is reason to believe that the productivity of 3D printing
with regard to the COVID-19 pandemic is not fully understood. The aim of this paper is to investigate
the productivity of the most promising open source 3D printing solutions for the COVID-19 pandemic.
2. Materials and Methods
2.1. Gathering the Most Promising Open Source Solutions
An overview of 3D printers and resulting products used in the COVID-19 pandemic was
undertaken using multiple sources including, but not limited to, local newsletters, national government
press releases, social media, 3D printing newsletters, university and company webpages, and other
professional networks. Based on the collected data, the authors performed a clustering method and
selected the most popular and potential products and devices (Table 1) currently used in the COVID-19
pandemic. The selection process was limited to open source parts.
2.2. 3D Printing and Cost Model
Three ISO/ASTM 3D printing processes, namely vat photopolymerization (VP), material extrusion
(ME), and powder bed fusion (PBF), are most commonly used to produce parts in the COVID-19
pandemic. The ME process is the most widespread 3D printing technology to date. The VP process is
widely used in the medical field to print biocompatible materials. The PBF process is broadly used
for producing functional prototypes, end-use parts, and rapid tooling. Table 2 lists the 3D printing
machines and materials that are currently being used, or that can otherwise maintain the functional
integrity of the respective products. Further, alternative materials can also be used as stated in Table 2.
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Table 1. Products currently being manufactured using 3D printing in the COVID-19 pandemic.
Description Users Pandemic Demand 3D Model Source
Face mask
(filter is attached separately)
Frontline workers: hospital staff, paramedics, law
enforcement authorities, etc.—individual people
Very high
> 10 billion https://amaskforall.com/
Face shield (3D printed holder)
















Table 2. 3D Printing technologies and alternatives.
ISO/ASTM
Technology Class Equipment & Material
Layer
Thickness Notes Sterilization Alternatives
VAT
Photopolymerization
Form 2TM & Dental SG.
(Formlabs Inc., USA)
0.1 mm Biocompatible material, needspost-curing and autoclaving Autoclave
Vat photopolymerization
technologies with material approved
for medical use
Material Extrusion
uPrintTM SE Plus & ABS
(Stratasys Ltd., Israel)
0.33 mm Material not medically approved,product might not be airtight Isopropyl
alcohol
Other material extrusion equipment
and materials, approved material
would be beneficialUltimakerTM 2 & ABS
(Ultimaker BV, Dutch)
0.1 mm Material not medically approved,product might not be airtight
Powder Bed Fusion
3DSystemsTM ProX SLS 500 &
DuraFormProX PA (3D Systems
Inc., USA)
0.1 mm Biocompatible material Autoclave Powder bed fusion technologies withapproved material for medical use
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The build volume of the respective 3D printing machines is often packed/nested in a manner that
aims to fully maximize the number of parts within the build area, while maintaining a high probability
of a successful print. Though the productivity may be improved by completely packing/nesting the
build volume with different types of products in one batch to increase packing density, particularly in
the PBF process, this study focuses on identical products to fully pack the build volume for simplicity.
The pre-processing software of different 3D printing processes have an unidentical array of control
settings and build parameters, owing to different materials and fusing mechanisms. In principle, a
higher layer thickness than the one used in this study may be selected to manufacture the prescribed
parts, which would also decrease the print time per batch. However, parts manufactured with an
increased layer thickness can yield relatively lower quality and weaker strength. To this end, this study
employs standardized 3D printing parameters for both build and support structures prescribed by the
original equipment manufacturer (OEM), to confirm process assurance and repeatability of results.
The supports were generated using OEM algorithms for the certified material profiles.
Figure 1 shows the packing arrangements of products in different build volumes that enable a
good build solution. For example, the nasal swabs intended to be manufactured through the PBF
process were not stacked over each other, because the consecutive addition of such a long and narrow
geometry would increase the risk of an unsuccessful end result in the build. This research opts for a
more pragmatic approach, in which the main focus is on the 3D printing process itself, and the in-depth
analyses for post-processing steps, sterilization, and cost of delivery are largely simplified.
A cost model with five components was used in this research. The 3D printing machine and
its maintenance, raw material, labor, overhead, and sterilization are the basic cost components. By
employing this model, we estimated the cost of producing and sterilizing four exemplar medical
parts, namely face masks, nasal swabs, face shield holders, and Venturi valves, using four 3D printing
machines with different raw materials and varying batch sizes. Different batch sizes for an identical 3D
printing machine have also been selected, to highlight the effect of batch size on the costs related to the
pre- and post-processing. In total, 17 experiments were conducted. The setting of the experiments, the
data, and the assumptions used to create the cost models are presented in Tables 3–5. Data regarding
the build times and material consumptions for the experiments was extracted from the OEM software
of the 3D printing machines, because this was the most accessible means of data. The software were
PreForm 2.20.0, GrabCAD 1.40.28.60898, Ultimaker Cura 4.5.0, and 3DSprint 2.13.0 for Form 2TM,
uPrintTM SE Plus, UltimakerTM 2, and 3DSystemsTM ProX SLS 500, respectively.
The assumptions regarding the cost of procuring the 3D printing machine and the estimated
annual maintenance are presented in Table 4. Moreover, the hourly labor cost for the pre- and
post-processing of the print job was assumed to be 15 € at a minimum hourly wage, and the duration
of labor requirement for each print job was estimated through expert opinion. The cost and method
of sterilization was extracted from the literature for the 17 experiments, as shown in Table 5. Parts
produced from Dental SG and Polyamide 12 can be sterilized by an autoclave, while the ABS parts
require submersion in a C3H8O [26] solution.
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Table 3. Experiment settings and model parameters.







Formlabs Form 2 Dental SG 2.58 400 12.27
2 3DSystems ProX SLS 500 PA12 57.46 3254 37.98
3
Venturi valve
Formlabs Form 2 Dental SG 2.58 18 8.03




6 10.19 47 108.45
7 uPrint SE Plus 6.26 24 33.75
8
Face mask + lid
Formlabs Form 2 Dental SG 2.58 1 3.92




11 10.19 18 195.65
12 uPrint SE Plus 6.26 2 12.27
13
Face shield holder




15 10.19 10 76.35
16 uPrint SE Plus 6.26 1 3.48
17 Face shield holderSLS optimized 3DSystems ProX SLS 500 PA12 57.46 374 102.52
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(Annual Cost in k€)
Labor Cost
per Hour (€)
Labor Required per 3D Printer
(Person Hour per Run)
1 224 ml
Not needed
270 €/l 2.7 3 0.5
15
2
2 40.06 l 13.5 €/l 350 10 10 8
3 167 ml Included in the build 270 €/l 2.7 3 0.5 2
4 49.64 l Not needed 13.5 €/l 350 10 10 5
5 9 g 1 g 0.06 €/g 1.9 2 0.4 0.5
6 412 g 44 g 1.9 2 0.4 2
7 197 cm3 107 cm3 0.29 €/cm3 16 8 1 1
8 70 ml Included in the build 270 €/l 2.7 3 0.5 1.5
9 54.23 l Not needed 13.5 €/l 350 10 10 4
10 90 g 8 g 0.06 €/g 1.9 2 0.4 0.5
11 780 g 185 g 1.9 2 0.4 1.5
12 136 cm3 35 cm3 0.29 €/cm3 16 8 1 0.5
13 54.18 l Not needed 13.5 €/l 350 10 10 4
14 33 g 1 g 0.06 €/g 1.9 2 0.4 0.5
15 312 g 32 g 1.9 2 0.4 1
16 37 cm3 10 cm3 0.29 €/cm3 16 8 1 0.5
17 54.39 l Not needed 13.5 €/l 350 10 10 4
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13 Autoclave 15 - - 1 0.5 1.04
14
C3H8O - 9
1.0 - - -
15 5.0
16 C3H8O - 9 1.0 - - -
17 Autoclave 15 - - 1 0.5 1.04
Appl. Sci. 2020, 10, 4004 8 of 15
Appl. Sci. 2020, 10, x FOR PEER REVIEW 4 of 12 
 
prescribed by the original equipment manufacturer (OEM), to confirm process assurance and 
repeatability of results. The supports were generated using OEM algorithms for the certified material 
profiles. 
Figure 1 shows the packing arrangements of products in different build volumes that enable a 
good build solution. For example, the nasal swabs intended to be manufactured through the PBF 
process were not stacked over each other, because the consecutive addition of such a long and narrow 
geometry would increase the risk of an unsuccessful end result in the build. This research opts for a 
more pragmatic approach, in which the main focus is on the 3D printing process itself, and the in-
depth analyses for post-processing steps, sterilization, and cost of delivery are largely simplified. 
 
Figure 1. Packing solutions of parts in different build volumes: (a) nasal swab in Form 2; (b) face 
shield holder SLS optimized in ProX SLS 500; (c) face shield holder in ProX SLS 500; and (d) Venturi 
valve in Form 2. 
A cost model with five components was used in this research. The 3D printing machine and its 
maintenance, raw material, labor, overhead, and sterilization are the basic cost components. By 
employing this model, we estimated the cost of producing and sterilizing four exemplar medical 
parts, namely face masks, nasal swabs, face shield holders, and Venturi valves, using four 3D printing 
machines with different raw materials and varying batch sizes. Different batch sizes for an identical 
3D printing machine have also been selected, to highlight the effect of batch size on the costs related 
to the pre- and post-processing. In total, 17 experiments were conducted. The setting of the 
experiments, the data, and the assumptions used to create the cost models are presented in Tables 3, 
4, and 5. Data regarding the build times and material consumptions for the experiments was extracted 
from the OEM software of the 3D printing machines, because this was the most accessible means of 
data. The software were PreForm 2.20.0, GrabCAD 1.40.28.60898, Ultimaker Cura 4.5.0, and 3DSprint 
2.13.0 for Form 2TM, uPrintTM SE Plus, UltimakerTM 2, and 3DSystemsTM ProX SLS 500, respectively. 
Table 3. Experiment settings and model parameters. 
Figure 1. Packing solutions of parts in different build volumes: (a) nasal swab in Form 2; (b) face shield
holder SLS optimized in ProX SLS 500; (c) face shield holder in ProX SLS 500; and (d) Venturi valve in
Form 2.
3. Results
Products currently being manufactured using 3D printing in the COVID-19 pandemic are generally
face masks, face shi lds, nasal swabs, and Venturi valves (Table 1). The s imated cost and pr ductivity
of different products with different 3D printing technologies, when extrapolated over the estimated
amount of identical equipment in the market, are shown in Table 6. The results indicate the potential
number of products that can be manufactured with one set of equipment, and with all the equipment
available in the market. Table 7 lists the overall estimated costs. The most potential ones are those that
have a high productivity with a single set of equipment and widespread availability of equipment in
the market.
However, here are similar 3D printers from different manufacturers in the ma ket that ca be
used to manufacture these products devices using co arable materials. Thus, the total 3D
printing potential in the world is in fact conservatively estimated to be at least 10–100 times larger, and
therefore can have a huge impact on the lack of medical supply in the current situation. Furthermore,
it should be noted that certain 3D printing technologies are better for manufacturing specific types of
products than others. To this end, there is a need to deploy an optimal 3D printing technology for each
application to maximize the production of required parts.
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Table 6. The potential productivity of using 3D printing.
Exp. ID Description Equipment Batch Size ProductivityUnits/24h
Estimated No. of
Equipment in the World
Total Potential
Units/24h
1 Nasal swab Formlabs Form 2 400 783 50k 39130k
2 Nasal swab 3DSystems ProX SLS 500 3254 2056 1k 2056k
3 Venturi valve Formlabs Form 2 18 54 50k 2688k
4 Venturi valve 3DSystems ProX SLS 500 625 274 1k 274k
5 Venturi valve Ultimaker 2 1 11 100k 1058k
6 Venturi valve Ultimaker 2 47 10 100k 1040k
7 Venturi valve uPrint SE Plus 24 17 5k 85k
8 Face mask + lid Formlabs Form 2 1 6,1 50k 306k
9 Face mask + lid 3DSystems ProX SLS 500 120 79 1k 78k
10 Face mask + lid Ultimaker 2 2 2,4 100k 244k
11 Face mask + lid Ultimaker 2 18 2,2 100k 220k
12 Face mask + lid uPrint SE Plus 2 3,9 5k 19k
13 Face shield holder 3DSystems ProX SLS 500 88 56 1k 55k
14 Face shield holder Ultimaker 2 1 3,5 100k 350k
15 Face shield holder Ultimaker 2 10 3,1 100k 314k
16 Face shield holder uPrint SE Plus 1 6,9 5k 34k
17 Face shield holder(SLS optimized) 3DSystems ProX SLS 500 374 88 5k 437k
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Table 7. The cost analysis of medical parts.











Total Cost of Producing a
Single Item (€)
1 2.86 30 60.48 10 1.04 26.1 0.33
2 284.88 120 540.89 100 0.52 261.6 0.40
3 1.87 30 45.09 10 1.04 22 6.11
4 410.25 75 670.14 100 0.52 314 2.51
5 0.51 7.5 0.6 1 4.5 3.5 17.64
6 24.40 30 27.36 1 45 31.9 3.40
7 16.88 15 88.16 10 4.5 33.6 7.01
8 0.91 22.5 18.9 10 1.04 13.3 66.69
9 274.88 60 732.10 100 0.52 291.9 12.16
10 4.41 7.5 5.88 1 9 6.9 17.37
11 44.02 22.5 57.9 1 45 42.6 11.83
12 6.13 7.5 49.59 10 4.5 19.4 48.58
13 285 60 731.43 100 0.52 294.2 16.72
14 1.54 7.5 2.04 1 9 5.3 26.35
15 17.18 15 20.64 1 45 24.7 12.35
16 1.74 7.5 13.63 10 9.0 10.5 52.34
17 768.88 60 734.33 100 1.04 416.1 5.56
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The total cost for each 3D printed batch is calculated by the summation of machine acquisition
and maintenance costs, labor, raw materials, consumable items, sterilization, and a 25% overhead cost.
To estimate the individual cost per part, the total cost of 3D printing the batch is divided by the size of
the production batch. For instance, the cost of producing a batch of 400 nasal swabs using the Formlabs
Form 2 machine is about 130.5 €, which translates to 0.33 € for a single nasal swab. Similarly, the cost
of producing the same part on a ProX SLS 500, which is a larger industrial PBF machine, is 0.40 €, as
shown in Table 7. The total cost of producing a single item with different cost components is shown in
Figure 2. Two different batch sizes, used for the production of identical parts, in Ultimaker 2 confirm
that a percentage increase in costs is significantly lower than the percentage increase in batch size. This
is because certain pre- and post- processes, i.e., labor, sterilization, and overhead, which can be seen
as dominating factors for small batches in Figure 2, are inevitable, and possess higher throughput
capacity than just one or two parts.
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4. Discussion
This study discusses the potential of using 3D printing (additive manufacturing) to manufacture
products required during the COVID-19 pandemic in the year 2020. Examples of products include face
shields, respirators, nasal swabs, and ventilator parts. Face shields and respirators pose an interesting
challenge for manufacturers, to ensure that they are fabricated within the shortest time frame in which
the efficiency of the design and shortest build time is paramount. However, they need an assembly
phase, such as adding a transparent plastic shield or a filter. Parts for ventilators and nasal swabs pose
a more technical challenge for manufacturers in light of intellectual patent laws. All the products are
still required to have compliance with healthcare standards and regulations.
At the moment, some countries suffering from the pandemic have accelerated the approval process
for using 3D printing to produce supplies for hospitals. Countries currently facing critical shortage of
supplies have even had to bypass some stringent regulations and approval stages with the acceptance of
run-of-the-mill solutions. One problematic factor is also the availability of 3D models for certain parts.
Companies aim to protect their designs and their intellectual property (IP), but at the same time suffer
from their limited manufacturing capacity. 3D printing may allow for an increase in the availability of
manufacturing capacity to react quickly, but their unwillingness to share the designs will remain the
greatest challenge. Nevertheless, open source community platforms, designers, makers, artists, and
even some companies have started to embrace this movement to share their designs and have made
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collaborative development possible. This chain reaction has sped up the solutions remarkably because
people are able to incrementally innovate over each other, and there is a possibility to learn from what
others have done. This has been one of the biggest reasons why 3D printing applications related to
COVID-19 have been developed so rapidly.
Previous work has acknowledged that 3D printing can be used to support the spare parts
market [27,28]. However, it must be noted that patent laws regarding such 3D printed spare parts
will need to be further resolved in the future. The COVID-19 pandemic has increased the pressure
on manufacturers to make their designs freely available, particularly in cases where spares may not
be readily accessible due to disruption in production plants, logistics, and supply chains. Current
spare parts are stored as physical inventory for which logistic networks or deliveries may not be
functional. Lastly, if tooling is required to re-initiate production, this can contribute to increasing
costs for companies and end-users. Another area of contention is that “repairing patent-protected
products with digital spare parts could risk infringing upon the intellectual property rights (IPR) of
patent holders” [27]. For example, to repair a protected device using a spare part, part of the invention
may be reproduced, and thereby infringement can occur. Fortunately in most European jurisdictions,
infringement only occurs if repair activities are undertaken for commercial purposes, and private use is
therefore exempted [29]. The concept of “repair” is still interpreted differently in different EU member
states, in terms of legitimate repair or when repair counts as infringing upon the rights of the patentee.
There has been no agreement on the interpretation of “repair” in the EU, and further clarity is needed
as to what extent producing, transforming, assembling, or constructing a product is considered to
be “legitimate”.
To support the efforts towards the fight against COVID-19, the National Institutes of Health
(NIH) [30] in the U.S. has made the computer-aided design (CAD) models of PPE products freely
available on its website, and has also divided them into two categories. Non-critical products
include air exchangers, filter adaptors, in-line filter housing, and pneumotachometers. Products
that have safety implications include ventilator splitters, Venturi valves, and flow restriction devices
that pose a much greater risk if used or produced incorrectly. This digital library was created to
support the manufacturing of PPE and other medical devices in short supply due to the COVID-19
outbreak. The NIH, Food and Drug Administration (FDA), Veterans Affairs (VA), America Makes,
and contributors acknowledged that they cannot ensure the quality, safety, and efficacy of these
designs when manufactured without proper quality controls and processes. As a result, ASTM
International [30] has enabled public access to relevant ASTM standards used in the production and
testing of PPE such as for face masks, medical gowns, gloves, and hand sanitizers. Other efforts, such
as the U.K. Government Office for Product Safety and Standards, have also published guidelines to
assist manufacturing companies planning to convert their operations to produce PPE. These include
ways to have products approved for sale or to be donated to the government to be used by healthcare
workers. It also provides guidance on what manufacturers have to do to fulfil those obligations, and
contacts to U.K. Notified Bodies that can assess PPE for COVID-19 [31]. However, it must be noted
that at the time of writing, there are still no specific standards available when using 3D printing for the
production of PPE to ensure total compliance with healthcare protocols.
In terms of the digital value chain when designing and producing parts for 3D printing, the
ISO document, “ISO 17296-4:2016 Additive manufacturing - General principles - Overview of data
processing” [32], suggests that data exchange methods could include the file type, data enclosed
formatting of such data, and what this can be used for. Examples of suitable formats for data exchange
include .STL, .STEP, and .AMF. Of these, the .STL file is still the most commonly used format, and this
has been observed in the file formats available in the digital library for COVID-19 CAD files. One of
the drawbacks is that .STL files do not specify units. Newer file formats have been made available,
such as the .AMF file format that can contain metadata such as information of the CAD source, design
and production specifications, supplier information, and production data. The .AMF file format is also
able to support constellations that describe the build pack, stacking, nesting, or orientation of parts.
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The .AMF file format is also XML-based, and users with a text editor are able to quickly open, view,
and edit the metadata content. Other useful formats that could provide a more accurate and efficient
manufacturing workflow include the .3MF file format.
3D printing in a bridge manufacturing mode has tremendously supported the fight against the
COVID-19 pandemic [33]. Local or distributed manufacturing [34,35], supply chain modifications, and
enhanced education can help us achieve a more stable supply chain, as well as mitigate a number of
shortcomings [28,36,37]. The labor requirements for pre- and post-production steps of 3D printing,
in addition to the throughput of the 3D printer, limited range of raw materials, and multi-material
process constraints, call for further technological advancements to improve the competitiveness of 3D
printing, and to deal with raw material shortages [38].
This study was limited to open source parts because they are accessible to everyone, and therefore
have the biggest impact. The work used few exemplar parts to highlight the potential of 3D printing,
however there is a wide range of similar open source parts made available in open access repositories.
Future studies are recommended to focus on the technical verification of the parts. Cost and productivity
models are estimations, and are simplified to provide valuable insights about the cost structure and
productivity that 3D printing is capable of achieving in the COVID-19 pandemic.
5. Conclusions
To fully capitalize on the use of 3D printing during the COVID-19 pandemic for the production
of parts in a state of emergency requires a technical know-how and understanding of technologies
and materials that will conform to the quality and functional integrity of the intended products. In
the ongoing viral outbreak, there is a very high demand for PPE, swabs, and spare parts, due to the
breakdown of global supply chains. On the basis of the findings, our analysis provides statistical
evidence that the most potential healthcare products that can be manufactured using 3D printing are
those that have a high productivity with a single set of equipment and with widespread availability of
equipment in the market. However, this new unregulated supply chain has also opened new questions
concerning product certification and IP. There is a pressing need to develop 3D printing medical
standards for current and future pandemics.
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